Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68 Dolacga PET for Liver Reserve in HCC
NCT06182865Not yet recruiting
- Sponsor
- National Atomic Research Institute
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Open-label, single-arm trial of Ga68-Dolacga in hepatocellular carcinoma (HCC), sponsored by National Atomic Research Institute. Primary endpoints: Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients before proton therapy at Day 1 and Measurement of liver reserve obtained from the Ga-68 Dolacga PET performed in HCC patients after proton therapy at Day 84. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
Ga68-Dolacga
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06182865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182865.